Pharmaceuticals

NLS Pharmaceutics

NLS and Kadimastem Merge to Form NewCelX and Expand DOXA Platform

NLS and Kadimastem Merge to Develop Type 1 Diabetes Cell Therapy Project

NLS Pharmaceutics released FY2025 Q2 earnings on October 6 (EST), actual revenue USD 0, actual EPS USD -0.2674

NLS Pharmaceutics released FY2025 Semi-Annual Earnings on October 6 (EST), with actual revenue of USD 0 and EPS of USD -1.0469

NLS Pharmaceutics released FY2025 Q1 earnings on October 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.5234

NLS Pharmaceutics Receives Milestone Funding Support from BIRD Foundation

NLS Pharmaceutics Completes $1 Million Equity Financing

NLS Pharmaceutics to Present New Preclinical Data on Mazindol ER at ASCP Annual Meeting

NLS Pharmaceutics released FY2024 9 Months Earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -2.4373

NLS Pharmaceutics released FY2024 Q4 earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -0.4958

NLS Pharmaceutics released FY2024 Q3 earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -0.4958

NLS Pharmaceutics released FY2024 Annual Earnings on May 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.6288 (forecast USD -1.6)

NLS Pharmaceutics Announces Positive Results for Mazindol Study

NLS Pharmaceutics AG released Q1 2024 earnings on October 18, 2024, with EPS -1.9414 USD and no revenue

NASDAQ Committee Approves NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements.

NLS Pharmaceuticals Signs Additional Bridge Loan Supplement Extending Loan Maturity to June 30, 2025

NLS Pharmaceutics released FY2023 Q3 earnings on May 15, 2024 (EST), with actual revenue of USD 0 and EPS of USD -2.3885

NLS Pharmaceutics released FY2023 Q4 earnings on May 15, 2024 (EST) with actual revenue of USD 0 and EPS of USD -2.3885

NLS Pharmaceutics released FY2023 9 Months Earnings on May 15, 2024 (EST) with actual revenue of USD 0 and EPS of USD -10.365

NLS Pharmaceuticals Receives Delisting Notice from Nasdaq

Processa Pharmaceuticals

Agape ATP

cbdMD

VYNE Therapeutics

Inspirato

Mega Fortune

Globavend

Andersen

DingDong

Udemy

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap